PCTC Funding Opportunity Announcements -- November 10, 2015

The NHLBI has just announced Funding Opportunity Announcements for an NHLBI Progenitor Cell Translational Consortium (U01) (RFA-HL-16-021) and for an NHLBI Progenitor Cell Translational Consortium Coordinating Center (U24) (RFA-HL-16-022).

NIH Funding Opportunity Announcement - November 2015

Stimulating Hematology Investigation: New Endeavors (SHINE) (R01)

FOA Number: PAS-16-033

Funding Purpose:

Steering Committee Conference Call - February 11, 2016

NHLBI Progenitor Cell Biology Consortium
Steering Committee Conference Call
Thursday, February 11, 2016, 2:00 – 3:30 p.m. (EST)
(1:00 – 2:30 p.m., CST; 12 Noon – 1:30 p.m., MST; 11:00 a.m. – 12:30 p.m., PST)

Agenda (draft)

1. Opening Remarks, Agenda, and Minutes of the October 14, 2015, PCBC Steering Committee Meeting – Victor Dzau

2. NHLBI Report – Denis Buxton



To provide the PCBC with a mechanism to quickly award small grants to junior faculty (less than 5 years from their appointment to Assistant Professor) research associates, fellows, postdocs, and graduate students to support a well-defined specific aim. The aim should involve at least one of the following, with priority given to proposals that incorporate two:


Lehanna Sanders, a graduate student in the Hatzopoulos Hub Site 11 has initiated this PCBC Blog. To join, contact Ling Tang (ltang@epi.umaryland.edu) or Andrea Lefever (alefever@epi.umaryland.edu) for permission to post. For blog charter click here.

Small Business Funding Opportunities from NIH

New Small Business Funding Opportunities from NIH: Bioreactors for Reparative Medicine

Protocols and Reagents

Platform for Sharing and Accessing Available Protocols and Reagents

The PCBC Synapse platform, in addition to storing data is a resource for the aggregation and dissemination of protocols and reagents for the consortium.

RFA Opportunities - September 2015

Requests for Applications:
Sickle Cell Disease in Sub-Saharan Africa: Collaborative Consortium (U24)

Akt1/protein Kinase B Enhances Transcriptional Reprogramming of Fibroblasts to Functional Cardiomyocytes; Schneider Hub Site 12

After a heart attack, millions to billions of cardiomyocytes are lost. Because the adult mammalian heart possesses little regenerative potential, a precipitous loss of cardiac function ensues. Patients with heart failure could benefit from repopulating injured areas of the heart with functional cardiomyocytes. To date, cellular transplantation has been therapeutically unsuccessful. Direct lineage reprogramming offers a new approach to repopulate cardiomyocytes in the heart.

La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors

Dr. Charles Hong’s group at the Vanderbilt Hub has signed a licensing agreement for clinical development of novel small molecule BMP inhibitors for rare genetic disease called fibrodysplasia ossificans progressiva, muscular dystrophy and variety of cancers that are driven by aberrant BMP signaling.  Earlier versions of BMP inhibitors that the Hong group developed, such as dorsomorphin and DMH1, have been widely used to direct differentiation of pluripotent stem cells toward cardiovascular, neuronal and other lineages.

Read more via the link below:


Copyright ©2013 NHLBI Progenitor Cell Biology Consortium.

University of Maryland School of Medicine logo

National Heart Blood and Lung Institute logo